Heart Failure with Reduced Ejection Fraction
Medically Reviewed by Dr. M. Salar Raza | Official SCFHS 2026 Blueprint
Clinical Pathway
Heart Failure with Reduced Ejection Fraction (HFrEF) is a clinical syndrome characterized by the heart's inability to pump sufficient blood to meet the body's metabolic demands due to impaired systolic function of the left ventricle, typically defined by a left ventricular ejection fraction (LVEF) of 40% or less. Treatment for HFrEF focuses on guideline-directed medical therapy (GDMT) including angiotensin receptor-neprilysin inhibitors (ARNI), beta-blockers, mineralocorticoid receptor antagonists (MRA), and sodium-glucose cotransporter-2 (SGLT2) inhibitors to reduce mortality and morbidity. Diuretics are used for symptom relief from congestion, and device therapies like implantable cardioverter-defibrillators (ICD) or cardiac resynchronization therapy (CRT) may be indicated for selected patients. Lifestyle modifications, such as dietary sodium restriction and fluid management, are also crucial. Patients commonly present with progressive exertional dyspnea, orthopnea, paroxysmal nocturnal dyspnea, and fatigue due to reduced forward flow. Physical signs may include peripheral edema, jugular venous distension, pulmonary rales (crackles), an S3 gallop, and hepatomegaly, indicating fluid congestion.
Clinical Reasoning
HFrEF primarily involves a reduction in the left ventricle's contractile function, often due to damage or remodeling of the myocardium. This leads to decreased cardiac output, increased ventricular filling pressures, and activation of compensatory neurohumoral mechanisms (e.g., renin-angiotensin-aldosterone system, sympathetic nervous system) which, over time, cause further maladaptive ventricular remodeling, fluid retention, and systemic vasoconstriction, perpetuating the cycle of heart failure. HFrEF is a chronic, progressive condition with significant morbidity and mortality, but prognosis has substantially improved with the advent of GDMT and device therapies. While it remains a serious condition, early diagnosis and adherence to comprehensive treatment can slow disease progression, reduce hospitalizations, improve quality of life, and extend life expectancy. Coronary Artery Disease (especially prior myocardial infarction),Hypertension,Diabetes Mellitus,Valvular Heart Disease,Dilated Cardiomyopathy (e.g., idiopathic, viral),Chronic Kidney Disease
Sample MCQ
A 55-year-old man with symptomatic heart failure with reduced ejection fraction (HFrEF) presents for a follow-up. He reports persistent dyspnea on exertion and fatigue despite current diuretic therapy. Which of the following medications is associated with a reduced mortality rate in heart failure?
- ADigoxin
- BDiuretics
- CAnticoagulants
- DAngiotensin-converting enzyme (ACE) inhibitors
Correct Answer: D
### TLDR **Angiotensin-converting enzyme (ACE) inhibitors** are a cornerstone of heart failure with reduced ejection fraction (HFrEF) therapy, uniquely proven to reduce mortality. While other medications manage symptoms or prevent complications, ACE inhibitors directly impact long-term survival by favorably remodeling the cardiovascular system. ### Comparison Table | Option | Mechanism | Clinical Nuance | Key Distinction | |:---|:---|:---|:---| | Digoxin | Na+/K+-ATPase inhibition; ↑ myocardial contractility; ↓ HR. | Symptom control (dyspnea, fatigue); no mortality benefit. | Symptomatic only; narrow therapeutic index; no survival advantage. | | Diuretics | Increase sodium/water excretion; reduce preload and congestion. | Primary treatment for fluid overload symptoms (dyspnea, edema). | Symptom relief only; no evidence for mortality reduction. | | Anticoagulants | Prevent clot formation (e.g., in AFib, prior VTE). | Indicated for specific comorbid conditions; not routine for all HFrEF. | Prevent thromboembolism, not direct HFrEF mortality reduction. | | **Angiotensin-converting enzyme (ACE) inhibitors** | Block RAAS; prevent vasoconstriction, sodium/water retention, remodeling. | Foundational therapy for HFrEF; reduces morbidity and mortality. | Proven to reduce all-cause mortality and hospitalizations in HFrEF. | ### Detailed Breakdown The question asks about medications associated with a reduced mortality rate in heart failure. This targets guideline-directed medical therapies (GDMT) that have shown significant survival benefits in clinical trials. **Angiotensin-converting enzyme (ACE) inhibitors** are correct because they are foundational therapy for HFrEF and have consistently demonstrated a reduction in all-cause mortality and hospitalizations. Their mechanism involves blocking the conversion of angiotensin I to angiotensin II, leading to vasodilation, decreased aldosterone secretion, reduced sympathetic activity, and inhibition of cardiac remodeling. This multifaceted action improves cardiac function and prevents disease progression, directly translating to improved survival. Let's examine why the other options are incorrect regarding mortality reduction: * **Digoxin** is a positive inotropic agent that can improve symptoms, reduce hospitalizations for heart failure, and slow the heart rate in patients with concomitant atrial fibrillation. However, clinical trials have not shown a mortality benefit for digoxin in HFrEF; its role is primarily for symptom management. * **Diuretics** (e.g., furosemide, torsemide) are crucial for managing symptoms of fluid overload in HFrEF, such as dyspnea and peripheral edema. They reduce intravascular volume, thereby decreasing preload and congestion. While essential for symptomatic relief and improving quality of life, diuretics do not alter the underlying disease progression or reduce mortality in HFrEF. * **Anticoagulants** (e.g., warfarin, direct oral anticoagulants) are indicated for specific conditions that often coexist with HFrEF, such as atrial fibrillation, a history of thromboembolic events (e.g., stroke, pulmonary embolism), or documented left ventricular thrombus. They prevent clot formation and subsequent complications. However, anticoagulants are not routinely recommended for all HFrEF patients without these specific indications, and they do not directly reduce the overall mortality associated with heart failure itself. Their benefit is in preventing thromboembolic events, not in modifying the HFrEF disease process that leads to mortality.
Related Clinical Topics
AIDS
AIDS (Acquired Immunodeficiency Syndrome) is the final, most severe stage of HIV infection, characterized by a profoundly compromised immune system that makes individuals highly susceptible to opportunistic infections and certain cancers. It is diagnosed when the CD4+ T-cell count drops below 200 cells/mm³ or when specific AIDS-defining opportunistic illnesses develop. The cornerstone of AIDS treatment is highly active antiretroviral therapy (HAART), a combination of drugs that suppress HIV replication, preserve immune function, and prevent further progression. HAART significantly reduces viral load, increases CD4+ T-cell counts, and improves overall health. Treatment also includes prophylactic antibiotics to prevent opportunistic infections and specific therapies for any active infections or cancers. Symptoms of AIDS are primarily due to the opportunistic infections and cancers that take advantage of the severely weakened immune system. Common manifestations include persistent fever, chronic diarrhea, significant unintentional weight loss, night sweats, fatigue, swollen lymph nodes, and recurrent severe infections like Pneumocystis pneumonia, Kaposi's sarcoma, and toxoplasmosis. Neurological complications such as AIDS dementia complex can also occur.
Bradycardia
Bradycardia is a medical condition characterized by a slower than normal heart rate, typically defined as fewer than 60 beats per minute (bpm) in adults. While sometimes physiological and benign, it can also indicate underlying cardiovascular or systemic issues that impair the heart's ability to effectively pump blood. Treatment for bradycardia depends on its underlying cause, severity, and the presence of symptoms. Asymptomatic bradycardia, especially in athletes, often requires no intervention. Symptomatic bradycardia may necessitate discontinuing or adjusting causative medications, treating underlying conditions, or in severe cases, implanting a permanent pacemaker to regulate heart rhythm. Acute, unstable bradycardia may require intravenous atropine or temporary pacing. Clinical manifestations range from asymptomatic presentation to severe symptoms depending on the degree of bradycardia and the patient's cardiovascular reserve. Common symptoms include fatigue, dizziness, lightheadedness, syncope (fainting), shortness of breath, and chest pain. In critical cases, it can lead to confusion, hypotension, and signs of organ hypoperfusion.
Chronic Hepatitis C Virus infection
Chronic Hepatitis C Virus (HCV) infection is a persistent inflammatory condition of the liver caused by the hepatitis C virus, defined by the presence of detectable HCV RNA for at least six months. This long-term infection can progressively lead to significant liver damage, including fibrosis, cirrhosis, and hepatocellular carcinoma. Current treatment primarily involves direct-acting antiviral (DAA) medications, which are highly effective oral regimens targeting specific viral proteins to inhibit HCV replication. These therapies typically achieve a sustained virologic response (SVR) in over 95% of patients, effectively curing the infection. Treatment duration usually ranges from 8 to 12 weeks, depending on the specific regimen and patient factors. Chronic HCV infection is often asymptomatic for many years, leading to a silent progression of liver disease. When symptoms do appear, they are often non-specific, such as fatigue, malaise, nausea, and right upper quadrant discomfort. As the disease advances to cirrhosis, signs of liver decompensation may emerge, including jaundice, ascites, peripheral edema, spider angiomata, and hepatic encephalopathy.
SMLE Preparation Resources
Master the 2026 SMLE
Explore more clinical protocols in the SMLEREVISE Clinical Knowledge Library.
Try the QBank & Scaled Mocks